Enanta Pharmaceuticals Inc. Company Profile
NASDAQ: ENTAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 12.10 0.00%
Enanta Pharmaceuticals at a glance
Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Watertown, MA. Enanta Pharmaceuticals is led by Dr. Jay R. Luly Ph.D. and employs about 120 people. The company's shares have traded publicly since 2013.
At a market capitalization of $352.4 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001177648, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Enanta Pharmaceuticals do?
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Enanta Pharmaceuticals Inc.
- Ticker
- NASDAQ: ENTA
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jay R. Luly Ph.D.
- Employees
- 120
- Headquarters
- 4 Kingsbury Avenue, Watertown, MA, United States
- Phone
- 617 607 0800
- Website
- enanta.com
- IPO year
- 2013
- Market cap
- $352.42M
- SEC CIK
- 0001177648
Companies similar to Enanta Pharmaceuticals
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EBSEmergent BioSolutions Inc. | 6.81 | -3.68% | $349.17M | vs ENTA |
| TTRXTurn Therapeutics Inc. | 11.39 | -5.87% | $345.89M | vs ENTA |
| ARCTArcturus Therapeutics Holdings Inc. | 12.87 | +0.82% | $365.80M | vs ENTA |
| RLMDRelmada Therapeutics Inc. | 3.17 | -2.46% | $338.14M | vs ENTA |
| GALTGalectin Therapeutics Inc. | 3.64 | +0.55% | $367.09M | vs ENTA |
| IRDOpus Genetics Inc. | 4.46 | +1.13% | $371.05M | vs ENTA |
| INDPIndaptus Therapeutics Inc. | 2.37 | +4.87% | $315.78M | vs ENTA |
| PRLDPrelude Therapeutics Incorporated | 3.88 | +1.31% | $309.64M | vs ENTA |